Home › Funds › Foresite Capital Management IV, LLC › XENE

Foresite Capital Management IV, LLC position in XENE

XENON PHARMACEUTICALS INC · Health Care

Foresite Capital Management IV, LLC reported holding 160,000 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$9.7M, representing 3.33% of its reported portfolio and ranking #5 among its reported holdings. Foresite Capital Management IV, LLC has disclosed XENE holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

Latest position (Q2 2026)160.00K sh
Reported value held$9.66M
Portfolio Weight3.33%
First reportedQ2 2025
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Foresite Capital Management IV, LLC's XENE position evolved

Foresite Capital Management IV, LLC first disclosed a stake in XENE in Q2 2025 at 160,000 shares (US$5.0M). The position peaked in Q2 2026 at 160,000 shares, worth US$9.7M. Across 5 filings, Foresite Capital Management IV, LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 160,000 shares valued at US$9.7M.

Quarter by quarter

QuarterSharesValueChange
Q2 2025 160.00K $5.01M New
Q3 2025 160.00K $6.42M Hold
Q4 2025 160.00K $7.17M Hold
Q1 2026 160.00K $9.30M Hold
Q2 2026 160.00K $9.66M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 44 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has Foresite Capital Management IV, LLC held XENE?

Foresite Capital Management IV, LLC has disclosed XENE holdings in 5 of the last 5 reported quarters, going back to Q2 2025.

What is Foresite Capital Management IV, LLC's current position in XENE?

As of Q2 2026, Foresite Capital Management IV, LLC holds 160.00K shares of XENE (XENON PHARMACEUTICALS INC), valued at $9.66M, representing 3.33% of its reported portfolio and ranking #5.

Has Foresite Capital Management IV, LLC been buying or selling XENE?

In the latest 13F filing (Q2 2026), Foresite Capital Management IV, LLC held unchanged its position in XENE. The position peaked in Q2 2026 at 160.00K shares.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.